Stefan Faderl, Guillermo Garcia-Manero, Elias Jabbour, Farhad Ravandi, Gautam Borthakur, Zeev Estrov, Varsha Gandhi, Anna L. Byrd, Monica Kwari, Jorge Cortes and Hagop M. Kantarjian A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome Cancer 118
Article first published online: 12 JUL 2011 | DOI: 10.1002/cncr.26327
Intravenous clofarabine was used at 2 different dose levels in patients with higher-risk myelodysplastic syndrome. Responses were comparable, but the lower dose level was less toxic. Activity has been noted in patients with and without prior exposure to DNA methyltransferase inhibitors.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field
Choose captcha format: Image or Audio. Click here if you need help.